PATENT CLAIM ANALYSIS

Application Number: 16209600
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "001210"]

Abstract:
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Claim (Index 48):
The compound of  claim 43 , wherein the pharmaceutical agent is selected from aspirin, ibuprofen, naproxen, celecoxib, rofecoxib, prednisolone, dexamethasone, hydroxychloroquine, cyclophosphamide, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, mitomycin C, bleomycin, mithramycin, sulfasalazine, leflunomide, mycophenolate, fingolimod, myriocin, chlorambucil, doxorubicin, nelarabine, cortisone, dexamethasone, prednisone, pralatrexate, vinblastine, bortezomib, thiotepa, nelarabine, daunorubicin hydrochloride, clofarabine, cytarabine, dasatinib, imatinib mesylate, ponatinib hydrochloride, vincristine sulfate, bendamustine hydrochloride, fludarabine phosphate, bosutinib, nilotinib, omacetaxinemepe succinate, anastrozole, capecitabine, letrozole, paclitaxel, gemcitabine, fulvestrant, tamoxifen, lapatinib, toremifene, ixabepilone, eribulin, albendazole, ivermectin, diethylcarbamazine, albendazole, doxycycline, closantel, maraviroc, enfuvirtide, deoxythymidine, zidovudine, stavudine, didanosine, zalcitabine, abacavir, lamivudine, emtricitabine, tenofovir, nevirapine, delavirdine, efavirenz, rilpivirine, raltegravir, elvitegravir, lopinavir, indinavir, nelfinavir, amprenavir, ritonavir, acyclovir, daunarubicin, ciclosporin, tacrolimus, sirolimus, mycophenolic acid, and cyclosporine.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 98.0
- Lexical Diversity: 1.3
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15113986', '14965549', '12364310', '15750471', '11329267']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7426457031747683
- 35 USC 102 Novelty (BERT): 0.5239086806710218
- Combined Prediction Score: 0.7207720009243936
- Mean Citation Score: 279.354174
- Max Citation Score: 284.09033
- Similarity Product: 167.2291936694634

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test